Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 23Thoracic 11Sarcoma 5Gynecologic 3Other solid neoplasm 2Head & Neck 2Tumor-Agnostic 1Genitourinary 1CNS 1Breast 1

Conditions

Advanced Renal Cell Carcinoma (aRCC) 1

Interventions

Docetaxel 191Gemcitabine 148Prednisone 142pembrolizumab 125enzalutamide 119Abiraterone Acetate 108Nivolumab 107Cisplatin 103Magnetic Resonance Spectroscopy 100Radiotherapy 95Sunitinib 94Leuprolide 91Carboplatin 82Specimen Handling 71Androgen Antagonists 63bicalutamide 60Radiosurgery 60Paclitaxel 59Goserelin 59Ipilimumab 57Bevacizumab 57apalutamide 53Sorafenib 53acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 51Everolimus 49cabozantinib 48abiraterone 46atezolizumab 45cabazitaxel 43durvalumab 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × envafolimab × Genitourinary × Clear all
NCT07159191 2025-09-08

Envafolimab Combined With Axitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma

Peking Union Medical College Hospital

Phase 2 Not yet recruiting
30 enrolled
Genitourinary

Advanced Renal Cell Carcinoma (aRCC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡